



National Securities Market Commission
Markets Directorate General
c/ Edison núm. 4
28006 Madrid

Colmenar Viejo (Madrid), March 21, 2018

Pursuant to article 228 of the consolidated text of the Spanish Securities Market Act, we hereby inform you of the following **SIGNIFICANT EVENT**:

“In relation to the Significant Fact n. 260272, Pharma Mar informs that the European Medicines Agency (EMA) has advanced to Pharma Mar that in the reexamination procedure requested by Pharma Mar in January 2018 in relation to the CHMP Opinion issued in December 2017 recommending not to grant the marketing authorization for Aplidin in the multiple myeloma indication, the CHMP has confirmed its previous negative Opinion”.